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Modulation of regional growth within specific segments of the bowel may have 27	
clinical value for several gastrointestinal conditions. We therefore examined the 28	
effects of different dietary protein sources on regional gut growth and luminal growth 29	
factor bioactivity as potential therapies.  Rats were fed for 14 days on isonitrogenous 30	
and isocaloric diets comprising elemental diet (ED) alone (which is known to cause 31	
gut atrophy), ED supplemented with casein or whey or a soya protein-rich feed. 32	
Effects on regional gut growth and intraluminal growth factor activity were then 33	
determined. Despite calorie intake being similar in all groups, soya rich feed caused 34	
20% extra total body weight gain. Stomach weight was highest on soya and casein 35	
diets. Soya enhanced diet caused greatest increase in small intestinal weight and 36	
preserved luminal growth factor activity at levels sufficient to increase proliferation in 37	
vitro. Regional small intestinal proliferation was highest in proximal segment in ED 38	
fed animals whereas distal small intestine proliferation was greater in soya fed 39	
animals. Colonic weight and proliferation throughout the colon was higher in animals 40	
receiving soya or whey supplemented feeds.  We conclude that specific protein 41	
supplementation with either soya, casein or whey may be beneficial to rest or increase 42	
growth in different regions of the bowel through mechanisms that include 43	
differentially affecting luminal growth factor bioactivity. These results have 44	
implications for targeting specific regions of the bowel for conditions such as Crohn’s 45	





Many intrinsic inflammatory and ingested injurious agents cause regional damage to 49	
the gut. These include Crohn’s disease (mainly affecting distal small intestine), 50	
ulcerative colitis (affecting colon) and non-steroidal inflammatory drugs (mainly 51	
affecting stomach and small intestine). Therapeutic targeting of drugs may occur 52	
through site specific release formulations or topical therapy (such as colonic enemas).   53	
As an alternative to pharmacological approaches, there is currently interest in using 54	
nutritional manipulation to both reduce the risk of relapse and for treatment when an 55	
injury is present. For example, elemental diets (ED), consisting of amino acids, 56	
mono/disaccharides and short/medium chain fatty acids, are of proven value in the 57	
treatment of inflammatory bowel disease, especially in children. 1, 2 The mechanism(s) 58	
of action of EDs are unclear but might include reducing systemic antigenic load and 59	
“resting” the bowel.  More recently, polymeric diets have been shown to be equally 60	
efficacious to ED 3, establishing the principal that selective additions to feeds may 61	
enhance efficacy without losing the beneficial effects of ED. Prolonged use of ED 62	
causes intestinal atrophy, particularly of the distal bowel, potentially increasing the 63	
risk of bacterial translocation and bacteraemia.4 Dietary formulations which reduce 64	
gut luminal antigenic load whilst minimizing the associated gut atrophy could, 65	
therefore, have therapeutic advantages. Similarly, because the gut is second only to 66	
the bone marrow in cell turnover, damage to the intestine is a common issue in 67	
patients undergoing chemotherapy (chemotherapy induced mucositis) and diets which 68	
reduce turnover while chemotherapy is administered or enhancing growth after 69	
treatment may also be useful.  70	
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The physiological control of gut growth is complex and poorly understood. Possible 71	
controlling mechanisms include alteration in circulating trophic hormones, local 72	
nutrition and luminal growth factors. We have previously suggested that ingestion of 73	
specific food proteins could influence gut growth by reducing the destruction of 74	
luminal growth factors, such as epidermal growth factor (EGF), through acting as 75	
competitive substrates for pancreatic proteases.5 In this model, the efficacy of the 76	
various proteins to stimulate gut growth would be dependent on their ability to act as 77	
substrate for pancreatic proteases, relative to the affinity of the luminal growth factors 78	
for the same enzymes. Support for this idea comes from an in vitro study that showed 79	
soya bean trypsin inhibitor or casein were better substrates than whey protein 80	
(“lactalbumin”) for human pancreatic proteases. Furthermore, the addition of soya 81	
protein or casein to human duodenal juice reduced its ability to digest EGF, whereas 82	
addition of whey protein or elemental diets did not.5 Soya protein or casein 83	
supplementation of feeds such as elemental diets might, therefore, be a clinically 84	
useful method of decreasing gut hypoplasia, while having a relatively minor effect on 85	
“antigenic load”.  86	
 87	
We, therefore, examined the effect of isocaloric and isonitrogenous diets comprising 88	
standard elemental diet (E028, Nutricia, Liverpool, UK), E028 supplemented with 89	
either casein (ED+C) or whey protein (ED+W), and a commercially available soya-90	
protein rich diet (SP, containing human food grade soya bean concentrate) on regional 91	
gut growth in rats and also assessed total “growth factor” bioactivity within the lumen 92	
of the small intestine. 93	
 94	




Three of the four test diets comprised standard elemental E028 (‘ED’, Nutricia 98	
Liverpool, UK) or variants of E028 containing whey protein (‘ED+W’, 12.5g/100g, 99	
the two major components of whey being α-lactoglobin and β-lactoglobin.)6  100	
or casein (‘ED+C’, 10.5g/100g). Both protein supplemented elemental diets where 101	
specifically produced for the studies by Nutricia Liverpool. The fourth group 102	
consisted of a commercially available soya protein rich diet (‘SP’, produced by SDS, 103	
Essex, UK). All four diets were similar in terms of digestible protein equivalence and 104	
amino-acid content but the SP diet had a higher carbohydrate content, lower added fat 105	
and contained some crude fibre (5.3%). Details of the various diets are shown in 106	
Supplemental Table 1.  107	
 108	
Protease inhibitory activity of feeds 109	
To determine trypsin inhibitory activity within the feeds, a standard BAPNA substrate 110	
assay7 was undertaken with concentrations of trypsin (0 - 50 µg) added to generate a 111	
standard curve. Additional tubes, each containing 20 µg trypsin had varying 112	
concentrations of the feeds added and any effect on reduction of tryptic activity (due 113	
to competitive inhibition) determined. In addition, to reproduce the situation found in 114	
vivo, where the feeds would be exposed to gastric juice prior to entering the small 115	
intestine, additional samples were pre-incubated with pepsin (1mg/ml) for 1 h. at pH 2, 116	
37oC before neutralization and subsequent BAPNA analyses.  117	
 118	
Animal Experiments 119	
All experiments were performed in compliance with relevant United Kingdom laws 120	
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and guidelines.  All animal experiments were approved by the Local Institutional 121	
Animals Ethics Committees (Imperial College and Cancer Research UK) and 122	
performed under institutional guidelines. Studies were covered by the appropriate 123	
licences under the United Kingdom Home Office Animals Procedures Acts, 1986 and 124	
performed under the UK home office Animal Research: Reporting of In Vivo 125	
Experiments) guidelines (ARRIVE). 126	
 127	
Pilot Study: We initially examined the caloric intake of rats (5 per group) fed on the 128	
various diets if allowed access ad libitum. Dietary intake was similar with all of the 129	
ED groups but was 10% greater in SP diet fed animals (data not show). Dietary 130	
restriction of SP fed animals was, therefore, used for the main study to ensure equal 131	
caloric intake between the various groups. 132	
 133	
Main study: Forty adult male, Sprague-Dawley rats (Charles River, UK, 180-225g) 134	
were coded, weighed and randomized into the four diet groups (n=10 per group) and 135	
fed exclusively on these diets for 14 days. Animals remained in their wire bottomed 136	
cages in groups of 5 throughout the study. 137	
Food was given in 2-ring concentric aluminium containers designed to minimize food 138	
spillage. The food consumption of each cage with determined each day by back 139	
weighing, including the small amount of spilled food beneath the cages. 140	
 141	
Autopsy procedure and collection of samples. 142	
At the end of the 14 day study, rats were given vincristine sulphate by intraperitoneal 143	
injection (1mg/kg, Eli Lilly, Basingstoke, UK) and killed 2 h later. Analyses of tissue 144	
was performed using the methods published by our group previously.8 The weight and 145	
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unstretched length of the various portions of the gastrointestinal tract were measured.  146	
To assess the effect of these various diets on luminal growth factor activity, 1 ml of 147	
iced, normal saline was then lavaged through the small intestine, collected into 148	
Eppendorf tubes, snap frozen using frozen CO2 (dry ice) and stored at -70 0C until 149	
assay for growth factor activity.  150	
The stomach and samples of the small intestine and colon were then fixed in Carnoy’s 151	
fluid, and stored in 70% (volume/volume) ethanol. For the intestinal tissues, the 152	
position of the various samples was defined by expressing its harvest site as a 153	
percentage of that organs total length at 1.5, 50 and 90% small intestinal distance and 154	
can be considered as equivalent to duodenum, jejunum and ileum respectively. 155	
Similarly, 10, 50 and 90% colon can be considered as proximal, mid and distal colon. 156	
 157	
Analysis of tissue samples. 158	
Assessment of metaphase accumulation was performed on micro-dissected tissue 159	
using our well validated, previously published methods8 by a person blinded to the 160	
experiment. Briefly, tissues were sequentially rehydrated, hydrolyzed and stained with 161	
Schiff’s reagent (the Feulgen reaction) and transferred to 45% (volume/volume) acetic 162	
acid. The crypts were then teased apart under a dissecting microscope, transferred to a 163	
glass microscope slide, flattened gently beneath a coverslip and examined using a 164	
compound microscope. The number of blocked mitoses per crypt was counted and the 165	
mean for 20 crypts per animal per site determined and used in the subsequent one way 166	
analysis of variance (ANOVA). 167	
 168	
Analysis of luminal growth factor activity. 169	
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Analyses of luminal growth factor activity were determined using thymidine 170	
incorporation into primary rat hepatocytes as a bioassay and an EGF-standard curve 171	
as described previously by us.9,10 Briefly, to prepare primary rat hepatocytes for the in 172	
vitro assay of luminal growth factor activity, male Sprague-Dawley rats were 173	
anaesthetized using Hypnorm (Janssen Pharmaceutica-Crown Chemicals Ltd, 174	
Lamberhurst, Kent, UK) and hepatocytes isolated by in situ collagenase perfusion. 175	
The basic protocol consists of a two-step perfusion of the liver in situ, via the portal 176	
vein, first with calcium-free buffer followed by a calcium supplemented buffer 177	
containing collagenases. The digested liver was removed, the cells dispersed, filtered, 178	
collected by centrifugation and resuspended in a plating medium. For all studies, 179	
hepatocytes were grown in Williams E medium without L-glutamine (Gibco BRL, 180	
Paisley, UK) containing 5% fetal calf serum. Cell viability, determined by the ability 181	
to exclude 0.2% trypan blue, was greater than 80% in all experiments. 182	
 183	
Assay of growth factor activity: Various volumes (50 to 200 µl) of luminal perfusate 184	
was added to the wells. To assess the percentage of cells entering DNA synthesis, 185	
[3H] thymidine (2 mCi/well, 10 ml, Amersham International, Bucks, UK) was 186	
included in the cultures eight hours after the addition of test samples. The amount of 187	
[3H] thymidine incorporated was assessed biochemically, 18 hours after the addition 188	
of [3H] thymidine.  Cells were washed for 15 seconds with water using a Dynatech 189	
multimash automatic self-harvester and solubilized by incubation at 37oC for 1 h in 190	
200 µl of 1 M KOH. 50 µl of the cell extract was counted in a β-counter in 1 ml of 191	
scintillant (Optiphase safe, LKB-Pharmacia Wallac).  192	
 193	
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The increase in thymidine uptake was then expressed in terms of EGF-like bioactivity 194	
by determining the equivalent amount of EGF that was needed to be added to the 195	
hepatocytes, to stimulate a similar increase in thymidine uptake. Measurements of 196	




Data were analysed using one-way ANOVA with the different diets as the factor. 201	
Where a significant effect of diet was seen, individual comparisons were performed 202	
comparing against ED, using t-tests based on the residual and degrees of freedom 203	
obtained from the ANOVA, a method equivalent to repeated measures analysis. All 204	
data is expressed as mean +/- SEM unless stated. 205	
 206	
RESULTS 207	
Protease inhibitory activity of feeds 208	
In vitro assay of feeds showed higher trypsin inhibitory activity (136 mg trypsin 209	
inhibition per 100g feed) in SP feed, moderate amount in ED+C (42 mg trypsin 210	
inhibition per 100g feed) but much lower amounts in ED (13 mg/100g) or ED+W (15 211	
mg/100g). Samples which had been pre-incubated with pepsin at pH 2 to reproduce 212	
prior exposure to gastric contents gave similar results (SP 120 mg trypsin inhibition 213	
per 100g feed, ED+C 38 mg/100g, ED 13 mg/100g and ED+W 12 mg/100g). 214	
 215	
Animal study 216	
Dietary intake: Daily caloric consumption per cage for each of the groups were as 217	
follows ED; 696, 666 - 726 cal. (mean, range), ED+W; 718, 682 -7 59 cal., ED+C; 218	
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714, 695 - 742 cal., SP; 705 cal (no range as all food eaten each day). This gave an 219	
average daily calorie consumption of 139 per animal in the ED group, 144 in ED+W 220	
group, 144 in ED+C group and 141 in SP fed animals. The caloric consumption of all 221	
groups were, therefore, within 3% of each other (p = 0.085) although because of the 222	
different constituents of the SP diet, this resulted in SP fed animals receiving 223	
approximately 18% greater protein equivalent intake. 224	
 225	
Total body weight gain: All animals increased weight over the two-week test period. 226	
with ED group showing an average of 54.5 +/- 4.4 g increase. Compared to the ED 227	
diet, weight gain in ED+C and ED+W (48.5 +/- 3.2 g and 58.5 +/- 2.1 g, respectively) 228	
was not significantly different but was 20% greater in SP group (65.5 +/- 3.7 g, 229	
p<0.01).  230	
 231	
Stomach weight: Absolute stomach weights were similar in ED and ED+W groups 232	
but about 10% greater in the ED+C and SP groups (p<0.05 and 0.01 vs. ED, 233	
respectively, Figure 1A). 234	
 235	
Small intestine (SI) weight. proliferation and intraluminal growth factor assay: 236	
Animals fed on the elemental diets all had similar SI weight whereas SP group small 237	
intestinal weight was 17% heavier (p<0.01, Figure 1B). Correspondingly, luminal 238	
growth factor activity equivalent to 3.9 +/- 0.4 ng of EGF was present in SP group but 239	
unrecordable in all other groups.   240	
Small intestinal regional proliferation varied dependent on site with the different diets. 241	
Proximal small intestinal proliferation was greatest in the ED, with the other three 242	
groups being significantly lower (Figure 2A). In contrast, SP group had the highest 243	
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proliferation rate in the mid small intestine (significantly greater than ED+W and 244	
ED+C, Figure 3B) and this difference was particularly marked in the distal small 245	
intestine with SP having proliferation rate of 150% of the other diets (Fig 2C).  246	
 247	
Colon weight and proliferation: Compared to ED fed animals, total colonic weight 248	
was 15% higher in ED+W animals and 50% higher in SP animals (both p<0.01, 249	
Figure 1C). Regional proliferation data was similar throughout the colon with ED+W 250	
and SP animals having 50% (proximal colon), 80% (mid colon) and 120% (distal 251	
colon) higher proliferation compared to ED or ED+C groups (p<0.01, Figure 3). 252	
 253	
DISCUSSION 254	
We have shown different dietary protein sources cause differential regional effects on 255	
gut growth and proliferation and that diets containing soya protein result in increased 256	
small intestinal luminal growth factor activity.  257	
 258	
Care was taken to ensure caloric intake of the groups were comparable to remove a 259	
potential confounding factor. We used fourteen days dietary intervention to reflect 260	
what would likely be used in a clinical setting in situations such as pre- or post- 261	
chemotherapy intervention. We used a rat hepatocyte system to assay intraluminal 262	
growth factor activity as this is a robust, reproducible method to determine relative 263	
bioactivity of EGF-R type ligands in the gut lumen and has the advantage over most 264	
cell lines of maintaining viability in the presence of bile and other luminal contents.9, 265	
10 The in vitro trypsin (inhibition) assay is a simple robust system to examine 266	
differential effects of food substances and builds on our earlier in vitro work5 showing 267	
that soya-bean trypsin inhibitor causes marked trypsin inhibition, casein causes 268	
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moderate trypsin inhibition (probably acting as a competitive substrate), whereas ED 269	
or whey have very limited inhibitory activity.   270	
 271	
The trophic effects of the various diets differed dependent on which region of the gut 272	
was analyzed. Compared to ED diet, stomach weight was better maintained in ED+C 273	
and SP rats. The effect of ED+C may be due to casein being precipitated in stomach 274	
acid, delaying gastric emptying, whereas rapid transit into the small intestine is seen 275	
in ED or ED+W animals.11  276	
 277	
The most notable finding of the ED diet was the much higher proliferation rate seen in 278	
the proximal small intestine compared to the other diets. This is probably as a result of 279	
rapid transit into the proximal intestine, where the ED constituents are rapidly 280	
adsorbed. This finding could be explained by the luminal workload hypothesis that 281	
suggests that regions actively involved in digestion/absorption have increased 282	
proliferation. This would also explain the low mitotic level seen in more distal regions 283	
of the small bowel as the majority of the feed would have been adsorbed more 284	
proximally.  285	
 286	
The most notable effects of ED+W were the increased weight and proliferation of the 287	
colon. Several potential mechanisms might have relevance in explaining these 288	
findings.  Changes in circulating trophic factors such as glucagon-like peptide-2 289	
(GLP-2) may have relevance although it is noteworthy that the trophic effect was 290	
restricted to the colon and not the small intestine. GLP-2 is produced by the ileum and 291	
colon, is trophic to the small intestine and colon and is rapidly degraded by tissue 292	
DPP-IV (dipeptidyl peptidase 4). Liu and co-workers showed oral whey 293	
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supplementation decreased colonic tissue DPP-IV in rats receiving continuous 294	
intravenous GLP-2, possibly increasing local colonic tissue GLP-2 levels.12 Therefore, 295	
even if circulating levels of GLP-2 remain stable, local changes in DPP-IV as a result 296	
of dietary manipulation may alter local concentrations. A further mechanism that 297	
would explain our results is our finding that whey proteins are poor substrates for 298	
luminal proteases when compared against casein or soya. The amount of nutrient 299	
reaching the terminal bowel is, therefore, likely to be higher in the ED+W compared 300	
to the other groups. Support for this idea comes from recent studies showing whey 301	
supplementation increased colonic short chain fatty acids (SCFAs) concentrations, a 302	
known substrate for colonocytes.13 Further studies to determine the importance of 303	
colonic bacteria in maintaining the growth of the colon in these animals could include 304	
measurement of colonic SCFAs or use of ‘germ free’ animals.  305	
 306	
The most notable effects of the SP diet in the current studies were the increased total 307	
body weight gain, the increased small and large bowel growth and the finding that 308	
bioactive growth factor activity was present in small intestinal washings. The 309	
additional increase in body weight in the SP-fed group was not due to differences in 310	
total calorie intake as these were well matched across the groups although it should be 311	
noted that the SP group received a slightly higher percentage of their calories from 312	
protein. We have previously suggested that control of intestinal growth might be 313	
mediated by changes in intraluminal growth factor concentrations, with the trophic 314	
effect dependent on the relative affinity of the luminal proteases for the ingested food 315	
and the luminal growth factors.5 This idea was supported by our findings that 316	
pancreatic diversion away from the gut lumen increases luminal growth factor 317	
concentrations and caused associated regional hypertrophy.5 The current studies 318	
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extend these findings showing that ingestion of soy based proteins (which includes 319	
soya bean trypsin inhibitor) are effective competitive substrates for luminal proteases 320	
in vivo, allowing luminal growth factors such as EGF to survive better than when 321	
animals are fed whey or casein.  These findings may have relevance to the trophic 322	
effect on the small and large intestine although it must be noted that the SP diet 323	
contained some fibre which may have relevance for colonic growth through acting as 324	
a fuel source for colonic bacteria, increasing colonic SCFAs levels in a similar way to 325	
that discussed for the whey fed animals. Further studies examining ED supplemented 326	
with pure soya protein which has had the fibre further reduced, combined with 327	
measurement of colonic SCFAs and possibly the use of germ-free animals could help 328	
address this question. 329	
 330	
There is currently much interest in the use of dietary proteins for the prevention and 331	
treatment of ill health.14 Our findings that dietary manipulation can cause regional 332	
changes in gut growth and also modulates luminal growth factor levels has potential 333	
clinical relevance. ED or polymeric diets are of proven benefit for Crohn’s disease, a 334	
condition that predominantly affects the small intestine. Specific protein 335	
supplementation of ED with whey may have advantages in “resting” the small 336	
intestine while preserving colonic growth, which among other advantages should 337	
reduce the risk of bacterial translocation. Supplementation of ED with soy protein 338	
may have the advantage of locally increasing luminal EGF levels, facilitating repair in 339	
a similar way to that shown by us in treating ulcerative colitis with topical therapy.15 340	
Further studies examining the effect of these proteins on intraluminal growth factor 341	
concentrations and injury and repair in animal models of inflammatory bowel disease 342	
appear warranted but go beyond the scope of this paper. Similarly, chemotherapy 343	
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induced injury to the gut is a common side effect of high dose chemotherapy and 344	
systemic administration of several different growth factors to promote repair have 345	
been tested or are being assessed.16  Dietary manipulation to reduce gut cellular 346	
turnover prior to treatment of non-gut tumours using systemic chemotherapy (to 347	
reduce gut side effects) and/or to increase gut proliferation post treatment, therefore, 348	
has potential therapeutic advantage by locally increasing luminal growth factor 349	
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FIGURE LEGENDS  408	
Figure 1. Effect of diets on percentage change in gastrointestinal weight 409	
Animals were fed for two weeks on isonitrogenous feeds comprising elemental diet 410	
(ED) alone, ED supplemented with milk whey (ED+W), ED supplemented with 411	
casein (ED+C) or fed a commercial soya protein rich diet (SP). All groups received 412	
similar total calorie intake. Changes in weight of the stomach (A), small intestine (B) 413	
and colon (C) after the two-week period were expressed as % change compared to 414	
that of animals fed ED diet. * and ** signifies p < 0.05 and p < 0.01, respectively 415	
compared with ED. 416	
  417	
Figure 2. Effects of diets on small intestinal mitosis. 418	
All animals on the various diets were injected with vincristine two hours prior to 419	
killing to allow assessment of rate of mitosis. Tissue was microdissected and data 420	
expressed as number of mitosis per crypt. The three regions analyzed were located 421	
according their position as a percentage of total small intestinal length; proximal small 422	
intestine (1.5%, duodenum, A), mid small intestine (50%, jejunum, B) and distal 423	
small intestine (90%, ileum, C). * and ** signifies p < 0.05 and p < 0.01, respectively 424	
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compared with ED. 425	
  426	
Figure 3. Effects of diets on colon mitosis. 427	
Colonic tissue from the same animals as Fig 3 was collected and the number of 428	
mitosis per crypt assessed.  The regions analyzed were located according their 429	
position as a percentage of total colonic length; 5% site of colon (proximal colon, A), 430	
50% site of colon (mid-colon, B), 90% site of colon (distal colon, C). * and ** 431	




















E028 and casein 
400g cans 
 
(ED + C) 
E028 and whey 
protein 
400g cans 
(ED + W) 
Soya protein 




12.5 13.8 13.8 12.9 
Energy content 
(kcal/100g) 
443 447 447 354 
Total amino acid 
content (g)  
15 15 15 14.22 
Fat content (g) 17.45 17.45 17.45 2.6 
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acids 
Crystalline amino 
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and canola oil 
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and canola oil 
Soya oil 
Nitrogen content (%) 2.2 2 2.1 2.35 
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1. ED – elemental diet 443	
2. ED + C - elemental diet + casein 444	
3. ED + W - elemental diet + whey protein 445	
4. SP-soya protein enhanced diet 446	
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